comunicati
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
COPYRIGHT LASICILIA.IT © RIPRODUZIONE RISERVATA
comunicati